{"id":"W4312114026","doi":"10.1038/s41408-022-00760-z","title":"Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia","year":2022,"lang":"en","type":"review","venue":"Blood Cancer Journal","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston Health Sciences Centre; University of Manitoba; CancerCare Manitoba","funders":"Cilag; Pharmacyclics; Kite Pharma; Canadian Institutes of Health Research; Ipsen; MorphoSys; Associazione Italiana per la Ricerca sul Cancro; Aptitude Health; Cancer Research UK; Ascentage Pharma; BeiGene; Celltrion; Hairy Cell Leukemia Foundation; Adaptive Biotechnologies; Astex Pharmaceuticals; TG Therapeutics; Genentech; Blood Cancer UK; Amicus Therapeutics; Incyte; Pfizer; Biogen; University of Rochester; CancerCare Manitoba Foundation; MEI Pharma; Daiichi-Sankyo; MacroGenics; Sunesis; University of Pittsburgh; National Cancer Institute; Servier; Gilead Sciences; Teva Pharmaceutical Industries; Leukemia and Lymphoma Society; Sanofi; Ipsen Biopharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; National Institutes of Health; Leukemia and Lymphoma Society of Canada; GlaxoSmithKline","keywords":"Minimal residual disease; Oncology; Medicine; Bone marrow; Internal medicine; Leukemia; Flow cytometry; Hematology; Hairy cell leukemia; Disease; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006987862,0.001141962,0.002658808,0.0031244,0.0006814558,0.00271057,0.00308852,0.007116171,0.007562153],"category_scores_gemma":[0.0119424,0.0004735581,0.001916166,0.002429493,0.001126435,0.003475471,0.002434507,0.006164728,0.005939118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001960942,"about_ca_system_score_gemma":0.004717032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001377071,"about_ca_topic_score_gemma":0.001849245,"domain_scores_codex":[0.9969245,0.0006616442,0.0007330406,0.0003724444,0.001041705,0.0002667396],"domain_scores_gemma":[0.9908209,0.00228425,0.0007600288,0.0001483024,0.005088745,0.0008976851],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009802757,0.0000274264,0.0001681627,0.009406115,0.00008182436,0.0003399116,0.00009305826,0.0001338352,0.000546034,0.001571707,0.7947029,0.192831],"study_design_scores_gemma":[0.00004084782,0.0000362762,0.0003724947,0.00693882,0.0001085926,0.0008695414,0.00008899743,0.00004422025,0.0001407855,0.001522247,0.9898112,0.00002595185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002694727,0.7758778,0.001091905,0.1086703,0.1080116,0.0001705845,0.0003899664,0.00006275392,0.005455654],"genre_scores_gemma":[0.002789549,0.8167596,0.002170702,0.1164906,0.0524242,0.0003046245,0.0008027968,0.00004804518,0.008209839],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007562153,"threshold_uncertainty_score":0.03695577,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.100051708671966,"score_gpt":0.4030415436695617,"score_spread":0.3029898349975957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}